PL3683235T3 - Przeciwciała przeciwko il-33 i ich zastosowania - Google Patents

Przeciwciała przeciwko il-33 i ich zastosowania

Info

Publication number
PL3683235T3
PL3683235T3 PL20159871.1T PL20159871T PL3683235T3 PL 3683235 T3 PL3683235 T3 PL 3683235T3 PL 20159871 T PL20159871 T PL 20159871T PL 3683235 T3 PL3683235 T3 PL 3683235T3
Authority
PL
Poland
Prior art keywords
antibodies
Prior art date
Application number
PL20159871.1T
Other languages
English (en)
Inventor
Andrew J. Murphy
Nicholas J. Papadopoulos
Jamie M. Orengo
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of PL3683235T3 publication Critical patent/PL3683235T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL20159871.1T 2013-03-13 2014-03-12 Przeciwciała przeciwko il-33 i ich zastosowania PL3683235T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361778687P 2013-03-13 2013-03-13
US201361819018P 2013-05-03 2013-05-03

Publications (1)

Publication Number Publication Date
PL3683235T3 true PL3683235T3 (pl) 2024-08-05

Family

ID=50678269

Family Applications (2)

Application Number Title Priority Date Filing Date
PL20159871.1T PL3683235T3 (pl) 2013-03-13 2014-03-12 Przeciwciała przeciwko il-33 i ich zastosowania
PL14722008T PL2970460T3 (pl) 2013-03-13 2014-03-12 Przeciwciała anty-IL-33 i ich zastosowania

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL14722008T PL2970460T3 (pl) 2013-03-13 2014-03-12 Przeciwciała anty-IL-33 i ich zastosowania

Country Status (29)

Country Link
US (6) US9453072B2 (pl)
EP (3) EP3683235B1 (pl)
JP (2) JP6479755B2 (pl)
KR (1) KR102103159B1 (pl)
CN (1) CN105051063B (pl)
AU (1) AU2014248839B2 (pl)
CA (1) CA2902172C (pl)
CL (2) CL2015002469A1 (pl)
DK (2) DK3683235T3 (pl)
EA (1) EA031745B1 (pl)
ES (2) ES2804592T3 (pl)
FI (1) FI3683235T3 (pl)
HR (2) HRP20240774T1 (pl)
HU (2) HUE051018T2 (pl)
IL (2) IL240354A0 (pl)
JO (1) JO3532B1 (pl)
LT (2) LT2970460T (pl)
MX (2) MX377712B (pl)
MY (3) MY209528A (pl)
PH (1) PH12015501656A1 (pl)
PL (2) PL3683235T3 (pl)
PT (2) PT2970460T (pl)
RS (2) RS60503B1 (pl)
SG (1) SG11201505745WA (pl)
SI (2) SI3683235T1 (pl)
TW (1) TWI633119B (pl)
UY (1) UY35417A (pl)
WO (1) WO2014164959A2 (pl)
ZA (1) ZA201505376B (pl)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
RU2641256C2 (ru) 2011-06-30 2018-01-16 Чугаи Сейяку Кабусики Кайся Гетеродимеризованный полипептид
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
CN113416257A (zh) 2011-11-30 2021-09-21 中外制药株式会社 包含进入细胞内以形成免疫复合体的搬运体(载体)的药物
UY34813A (es) 2012-05-18 2013-11-29 Amgen Inc Proteínas de unión a antígeno dirigidas contra el receptor st2
JP6306588B2 (ja) 2012-08-21 2018-04-04 サノフィ・バイオテクノロジー Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
TWI717591B (zh) 2012-08-24 2021-02-01 日商中外製藥股份有限公司 ＦｃγＲＩＩｂ特異性Ｆｃ區域變異體
JP6433297B2 (ja) 2012-12-27 2018-12-05 中外製薬株式会社 ヘテロ二量化ポリペプチド
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
EA034834B1 (ru) 2013-03-15 2020-03-26 Ридженерон Фармасьютикалз, Инк. Антагонисты il-33 и их применение
TWI636062B (zh) 2013-04-02 2018-09-21 中外製藥股份有限公司 Fc region variant
FI3088517T3 (fi) 2013-12-26 2023-11-30 Mitsubishi Tanabe Pharma Corp Ihmisen Anti-IL-33 neutraloiva monoklonaalinen vasta-aine
ES2866935T3 (es) * 2014-01-10 2021-10-20 Anaptysbio Inc Anticuerpos dirigidos contra interleucina-33 (IL-33)
EP3134120B1 (en) 2014-04-21 2024-01-24 The Children's Hospital of Philadelphia Compositions and methods for treating cytokine-related disorders
NO2785538T3 (pl) 2014-05-07 2018-08-04
CN107108721B (zh) 2014-09-29 2021-09-07 杜克大学 包含hiv-1包膜靶向臂的双特异性分子
US11708608B2 (en) * 2014-11-10 2023-07-25 Genentech, Inc. Therapeutic and diagnostic methods for IL-33-mediated disorders
TWI705976B (zh) 2014-11-10 2020-10-01 美商建南德克公司 抗介白素-33抗體及其用途
KR102650420B1 (ko) 2014-12-19 2024-03-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
CN112142844B (zh) 2015-02-05 2025-07-25 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
HK1247622A1 (zh) 2015-03-02 2018-09-28 180 Therapeutics Lp 利用il-33拮抗剂来治疗局部纤维化的方法
CA2982400C (en) 2015-03-31 2023-10-24 Medimmune Limited A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
AU2016246590B2 (en) * 2015-04-06 2021-10-07 Meso Scale Technologies, Llc. High throughput system for performing assays using electrochemiluminescence including a consumable shaking apparatus
TWI797060B (zh) 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
JP6858182B2 (ja) 2015-10-06 2021-04-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． インターロイキン３３（ｉｌ−３３）媒介疾患に関するバイオマーカーおよびその使用
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
EA201891628A1 (ru) * 2016-01-14 2018-12-28 Анаптисбайо, Инк. Ингибирование аллергической реакции с использованием ингибитора il-33
AU2017252527A1 (en) 2016-04-18 2018-11-08 Celldex Therapeutics, Inc. Agonistic antibodies that bind human CD40 and uses thereof
CN109069538A (zh) * 2016-04-22 2018-12-21 免疫医疗有限责任公司 Ilc2的功能可塑性、免疫和copd
KR20220147722A (ko) 2016-04-27 2022-11-03 애브비 인코포레이티드 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
EP3448888A1 (en) * 2016-04-27 2019-03-06 Pfizer Inc Anti-il-33 antibodies, compositions, methods and uses thereof
MX2019001448A (es) 2016-08-05 2019-09-13 Chugai Pharmaceutical Co Ltd Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8).
WO2018039499A1 (en) 2016-08-24 2018-03-01 Regeneron Pharmaceuticals, Inc. Host cell protein modification
JP7212821B2 (ja) * 2016-10-13 2023-01-26 チア・タイ・ティエンチン・ファーマシューティカル・グループ・カンパニー・リミテッド 抗ｌａｇ－３抗体および組成物
JOP20190093A1 (ar) * 2016-10-28 2019-04-25 Lilly Co Eli أجسام مضادة لـ il-33 واستخداماتها
TWI857389B (zh) 2016-12-01 2024-10-01 美商再生元醫藥公司 治療發炎症狀的方法
MY197534A (en) 2017-02-10 2023-06-21 Genentech Inc Anti-tryptase antibodies, compositions thereof, and uses thereof
CN108456251A (zh) * 2017-02-21 2018-08-28 上海君实生物医药科技股份有限公司 抗pd-l1抗体及其应用
WO2018156180A1 (en) 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use
EP3610041A1 (en) * 2017-04-13 2020-02-19 Regeneron Pharmaceuticals, Inc. Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1
JP7657440B2 (ja) 2017-06-12 2025-04-07 ブルーフィン バイオメディシン， インコーポレイテッド 抗－ｉｌ１ｒａｐ抗体および抗体薬物コンジュゲート
KR102659791B1 (ko) 2017-07-06 2024-04-23 리제너론 파마슈티칼스 인코포레이티드 당단백질을 만들기 위한 세포 배양 과정
SG11202001786PA (en) 2017-08-31 2020-03-30 Mitsubishi Tanabe Pharma Corp Il-33 antagonist-containing therapeutic agent for endometriosis
EP3710589A4 (en) 2017-11-14 2021-11-10 Chugai Seiyaku Kabushiki Kaisha ANTI-C1S ANTIBODIES AND METHOD OF USING
CN111479618B (zh) 2017-12-22 2022-08-02 瑞泽恩制药公司 用于表征药物产品杂质的系统和方法
EA202091689A1 (ru) 2018-01-31 2020-10-22 Ридженерон Фармасьютикалз, Инк. Система и способ определения характеристик примесей, представляющих собой варианты, отличающиеся по размеру и заряду, в продукте, представляющем собой лекарственное средство
TW202311746A (zh) 2018-02-02 2023-03-16 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
SG11202007564VA (en) 2018-02-09 2020-09-29 Genentech Inc Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
MX2020008988A (es) 2018-02-28 2020-09-28 Regeneron Pharma Sistemas y metodos para la identificacion de contaminantes virales.
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
MY202358A (en) 2018-03-19 2024-04-24 Regeneron Pharma Microchip capillary electrophoresis assays and reagents
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
IL277890B2 (en) * 2018-04-11 2024-03-01 Regeneron Pharma Methods for quantifying il-33
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
PE20210343A1 (es) 2018-08-10 2021-02-23 Chugai Pharmaceutical Co Ltd Molecula de union al antigeno anti grupo de diferenciacion 137 (cd137) y su uso
CN112218877B (zh) 2018-08-27 2025-07-25 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
BR112020026348A2 (pt) 2018-08-30 2021-03-30 Regeneron Pharmaceuticals, Inc. Método para avaliar a estequiometria e distribuição de tamanho de complexos de proteínas, para selecionar um medicamento de proteína principal e para caracterizar complexos de proteínas, e, composição farmacêutica
AU2020208396A1 (en) 2019-01-16 2021-05-20 Regeneron Pharmaceuticals, Inc. Methods for identifying free thiols in proteins
TWI861073B (zh) * 2019-03-21 2024-11-11 美商再生元醫藥公司 含有抗il-33抗體之穩定調配物
SG11202111255YA (en) * 2019-05-01 2021-11-29 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-33 antagonist
CN113785203A (zh) 2019-05-13 2021-12-10 里珍纳龙药品有限公司 改进的竞争性配体结合测定
AU2020275348A1 (en) 2019-05-15 2021-12-09 Chugai Seiyaku Kabushiki Kaisha An antigen-binding molecule, a pharmaceutical composition, and a method
MX2022000649A (es) 2019-07-16 2022-06-08 Sanofi Biotechnology Metodos para tratar o prevenir el asma mediante la administracion de un antagonista de il-4r.
PH12022550630A1 (en) 2019-09-24 2023-03-27 Regeneron Pharma Systems and methods for chromatography use and regeneration
US11560595B2 (en) 2019-10-03 2023-01-24 Dasman Diabetes Institute Method for preventing progression to type II Diabetes
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
CA3158366A1 (en) 2019-11-04 2021-05-14 Medimmune Limited Anti il-33 therapeutic agent fpr treating renal disorders
IL292443A (en) 2019-11-04 2022-06-01 Medimmune Ltd Methods for using IL-33 antagonists
CN114760986A (zh) 2019-11-25 2022-07-15 里珍纳龙药品有限公司 使用非水性乳液的持续释放调配物
JP2023508360A (ja) * 2019-12-23 2023-03-02 サノフィ・バイオテクノロジー Ｉｌ－３３アンタゴニストおよび／またはｉｌ－４ｒアンタゴニストを投与することによりアレルギー性喘息を治療するまたは予防するための方法
CN113214395A (zh) * 2020-01-21 2021-08-06 迈威(上海)生物科技股份有限公司 抗st2抗体及其应用
EP4354145B1 (en) 2020-01-21 2025-09-17 Regeneron Pharmaceuticals, Inc. Deglycosylation methods for electrophoresis of glycosylated proteins
AU2021236306A1 (en) 2020-03-13 2022-09-15 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
WO2021180858A1 (en) 2020-03-13 2021-09-16 Medimmune Limited Therapeutic methods for the treatment of subjects with risk alelles in il33
CA3176571A1 (en) 2020-04-06 2021-10-14 Medimmune Limited Treating acute respiratory distress syndrome with il-33 axis binding antagonists
WO2021211416A1 (en) * 2020-04-13 2021-10-21 Maddon Advisors Llc Ace2- and tmprss2-targeted compositions and methods for treating covid-19
IL297841A (en) 2020-05-11 2023-01-01 Medimmune Ltd Formulations of anti-il-33 antibodies
CA3178564A1 (en) * 2020-05-12 2021-11-18 Zhengping Zhang St2 antigen binding protein
KR102789102B1 (ko) * 2020-08-18 2025-03-28 성균관대학교산학협력단 Il-33 항체 또는 이의 항원 결합 단편
BR112023003273A2 (pt) 2020-08-31 2023-05-02 Regeneron Pharma Estratégias de alimentação de asparagina para melhorar desempenho da cultura celular e mitigar variantes da sequência de asparagina
CN114249825A (zh) * 2020-09-25 2022-03-29 三生国健药业（上海）股份有限公司 结合人il-33的抗体、其制备方法和用途
MX2023006077A (es) 2020-11-25 2023-06-06 Regeneron Pharma Formulaciones de liberacion sostenida mediante emulsificacion por membrana no acuosa.
KR20230121854A (ko) 2020-12-17 2023-08-21 리제너론 파아마슈티컬스, 인크. 단백질-캡슐화 마이크로겔의 제작
US12031151B2 (en) 2021-01-20 2024-07-09 Regeneron Pharmaceuticals, Inc. Methods of improving protein titer in cell culture
WO2022187323A1 (en) 2021-03-03 2022-09-09 Regeneron Pharmaceuticals, Inc. Systems and methods for quantifying and modifying protein viscosity
CA3211302A1 (en) 2021-03-26 2022-09-29 Ross Kenyon Methods and systems for developing mixing protocols
BR112023024984A2 (pt) 2021-06-01 2024-02-20 Regeneron Pharma Tampão de amostra de eletroforese aquosa, método para identificar contaminantes ou impurezas em uma amostra de droga proteica, e, kit
CN113493513B (zh) * 2021-06-30 2022-07-12 深圳大学 抗人il-33中和性自身抗体及其制备方法和应用
CN113603775B (zh) * 2021-09-03 2022-05-20 江苏荃信生物医药股份有限公司 抗人白介素-33单克隆抗体及其应用
TW202326138A (zh) 2021-09-08 2023-07-01 美商再生元醫藥公司 用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法
EP4405390A1 (en) 2021-09-20 2024-07-31 Regeneron Pharmaceuticals, Inc. Methods of controlling antibody heterogeneity
WO2023059803A1 (en) 2021-10-07 2023-04-13 Regeneron Pharmaceuticals, Inc. Ph meter calibration and correction
EP4413364A2 (en) 2021-10-07 2024-08-14 Regeneron Pharmaceuticals, Inc. Systems and methods of ph modeling and control
MX2024005090A (es) 2021-10-26 2024-07-19 Regeneron Pharma Sistemas y metodos para generar agua de laboratorio y distribuir agua de laboratorio a diferentes temperaturas.
JP2024544885A (ja) 2021-11-10 2024-12-05 ジェネンテック， インコーポレイテッド 抗インターロイキン－３３抗体及びその使用
AU2023228391A1 (en) * 2022-03-03 2024-09-19 Pfizer Inc. Multispecific antibodies binding to il-4, il-13 and/or tslp and uses thereof
JP2025508233A (ja) 2022-03-18 2025-03-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ポリペプチド変異体を分析するための方法およびシステム
TW202402790A (zh) 2022-03-25 2024-01-16 英商梅迪繆思有限公司 減少呼吸系統感染之方法
US20260056210A1 (en) 2022-08-19 2026-02-26 Medimmune Limited Method of selecting patients for treatment with an il-33 axis antagonist
CN120418653A (zh) 2022-12-16 2025-08-01 里珍纳龙药品有限公司 评估色谱柱完整性的方法和系统
US20240245779A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Methods of modeling liquid protein composition stability
WO2024158961A1 (en) 2023-01-25 2024-08-02 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
TW202445138A (zh) 2023-02-01 2024-11-16 美商再生元醫藥公司 用於生物巨分子分析之具質譜法的不對稱流場流分離
TW202446462A (zh) 2023-02-22 2024-12-01 美商再生元醫藥公司 系統適用性參數及管柱老化
TW202508625A (zh) 2023-05-01 2025-03-01 美商再生元醫藥公司 使用苯酚或苯甲醇之多劑量抗體藥物產品
KR102773101B1 (ko) 2023-08-28 2025-02-26 서울대학교산학협력단 세포독성능을 갖는 제2형 선천성 림프구 세포, 이의 제조방법 및 용도
JP7668943B2 (ja) * 2023-08-30 2025-04-25 ファイザー・インク 多重特異性抗体およびその使用
US20250086164A1 (en) 2023-09-08 2025-03-13 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
WO2025064403A2 (en) 2023-09-18 2025-03-27 Regeneron Pharmaceuticals, Inc. Methods and systems for developing chromatography protocols
TW202532098A (zh) 2023-09-29 2025-08-16 美商再生元醫藥公司 使用控制成核之冷凍乾燥
US20250129117A1 (en) 2023-10-18 2025-04-24 Regeneron Pharmaceuticals, Inc. Rapid purification of monoclonal antibody from in-process upstream cell culture material
AR134213A1 (es) 2023-11-02 2025-12-10 Regeneron Pharma Métodos para reducir la actividad de la lipasa mediante estrés
WO2025120567A1 (en) 2023-12-07 2025-06-12 Medimmune Limited Method of treatment of asthma
US20250230251A1 (en) 2023-12-20 2025-07-17 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rb) and related methods
WO2025166281A1 (en) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Platform for charge-detection mass spectrometry analysis of aavs
WO2025175164A1 (en) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
WO2025194043A1 (en) 2024-03-15 2025-09-18 Regeneron Pharmaceuticals, Inc. Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations
WO2025210099A1 (en) 2024-04-04 2025-10-09 Medimmune Limited Method of treatment and selecting a subject
WO2025242618A1 (en) 2024-05-20 2025-11-27 Medimmune Limited Bronchiectasis treatment
WO2025259840A1 (en) 2024-06-13 2025-12-18 Regeneron Pharmaceuticals, Inc. Methods and systems for scaled chromatography
WO2026025028A1 (en) 2024-07-26 2026-01-29 Regeneron Pharmaceuticals, Inc. Methods of making ultra-high concentrated protein formulations using lyophilization
WO2026060350A1 (en) 2024-09-13 2026-03-19 Regeneron Pharmaceuticals, Inc. Methods of improving photo stability and controlling formation of hmw species in biologic formulations, and biologic formulations produced by the methods

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US550362A (en) 1895-11-26 crosby
US1000056A (en) 1910-11-03 1911-08-08 Carlos Van Bergh Threshing-machine.
US1001164A (en) 1911-06-09 1911-08-22 Arthur W Porter Cotton-sweep.
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
US5576191A (en) 1994-06-17 1996-11-19 Immunex Corporation Cytokine that binds ST2
WO2004056868A2 (en) 2002-12-19 2004-07-08 Endocube Sas Nf-hev compositions and methods of use
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
US7666622B2 (en) 2005-10-19 2010-02-23 Regeneron Pharmaceuticals, Inc. Monomeric self-associating fusion polypeptides and therapeutic uses thereof
US8865645B2 (en) 2006-05-24 2014-10-21 Biogen Idec Ma Inc. Method of treating lung fibrosis using ST2 polypeptide
DK2374818T3 (da) 2006-06-02 2013-01-21 Regeneron Pharma Højaffinitetsantistoffer mod human IL-6-receptor
US7560530B1 (en) 2006-07-20 2009-07-14 Schering Corporation IL-33 receptor
EP2152740A1 (en) 2007-04-26 2010-02-17 Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin Products for altering il-33 activity and methods therefor
EP2069784A4 (en) 2007-05-18 2009-11-18 Medimmune Llc IL-33 IN INFLAMMATORY DISEASE
WO2009053098A1 (en) 2007-10-26 2009-04-30 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of caspase i-dependent cytokines in the treatment of neurodegenerative disorders
WO2011031600A1 (en) 2009-09-10 2011-03-17 Schering Corporation Use of il-33 antagonists to treat fibrotic disease
US9212227B2 (en) 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
UY34813A (es) 2012-05-18 2013-11-29 Amgen Inc Proteínas de unión a antígeno dirigidas contra el receptor st2
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
EA034834B1 (ru) 2013-03-15 2020-03-26 Ридженерон Фармасьютикалз, Инк. Антагонисты il-33 и их применение
FI3088517T3 (fi) 2013-12-26 2023-11-30 Mitsubishi Tanabe Pharma Corp Ihmisen Anti-IL-33 neutraloiva monoklonaalinen vasta-aine
ES2866935T3 (es) 2014-01-10 2021-10-20 Anaptysbio Inc Anticuerpos dirigidos contra interleucina-33 (IL-33)

Also Published As

Publication number Publication date
WO2014164959A2 (en) 2014-10-09
MY209528A (en) 2025-07-17
DK3683235T3 (da) 2024-07-08
US20240425580A1 (en) 2024-12-26
US12037388B2 (en) 2024-07-16
SG11201505745WA (en) 2015-08-28
KR20150126598A (ko) 2015-11-12
JP2016513644A (ja) 2016-05-16
CA2902172A1 (en) 2014-10-09
EP4403570A3 (en) 2024-10-02
PT2970460T (pt) 2020-06-02
KR102103159B1 (ko) 2020-05-29
CN105051063A (zh) 2015-11-11
MX2020012416A (es) 2021-02-09
BR112015020470A2 (pt) 2017-10-10
HUE067119T2 (hu) 2024-10-28
US20140271658A1 (en) 2014-09-18
AU2014248839B2 (en) 2019-01-03
MX377712B (es) 2025-03-11
TWI633119B (zh) 2018-08-21
US20200071396A1 (en) 2020-03-05
MY201923A (en) 2024-03-23
CA2902172C (en) 2024-04-02
DK2970460T3 (da) 2020-06-02
JP6479755B2 (ja) 2019-03-06
US9453072B2 (en) 2016-09-27
UY35417A (es) 2014-10-31
ES2983609T3 (es) 2024-10-23
US20160362487A1 (en) 2016-12-15
TW201522370A (zh) 2015-06-16
LT2970460T (lt) 2020-06-10
ZA201505376B (en) 2016-07-27
US10000564B2 (en) 2018-06-19
IL261743A (en) 2018-10-31
AU2014248839A1 (en) 2015-08-20
SI2970460T1 (sl) 2020-07-31
PH12015501656B1 (en) 2015-10-19
HRP20240774T1 (hr) 2024-09-13
EA031745B1 (ru) 2019-02-28
NZ710831A (en) 2021-04-30
CL2015002469A1 (es) 2016-06-10
US10519230B2 (en) 2019-12-31
HK1220467A1 (en) 2017-05-05
EP2970460A2 (en) 2016-01-20
EP3683235B1 (en) 2024-05-22
PT3683235T (pt) 2024-06-24
IL240354A0 (en) 2015-09-24
JO3532B1 (ar) 2020-07-05
CL2018000101A1 (es) 2018-07-06
US20180251542A1 (en) 2018-09-06
RS65586B1 (sr) 2024-06-28
WO2014164959A3 (en) 2015-02-19
HUE051018T2 (hu) 2021-01-28
MY174740A (en) 2020-05-13
LT3683235T (lt) 2024-06-25
US11104729B2 (en) 2021-08-31
MX2015010599A (es) 2015-12-15
PH12015501656A1 (en) 2015-10-19
ES2804592T3 (es) 2021-02-08
FI3683235T3 (fi) 2024-07-02
SI3683235T1 (sl) 2024-07-31
IL261743B (en) 2020-11-30
US20210363236A1 (en) 2021-11-25
EP3683235A1 (en) 2020-07-22
CN105051063B (zh) 2019-08-16
HRP20200846T1 (hr) 2020-08-21
RS60503B1 (sr) 2020-08-31
EP4403570A2 (en) 2024-07-24
PL2970460T3 (pl) 2020-10-05
JP6845876B2 (ja) 2021-03-24
EA201591716A1 (ru) 2016-07-29
JP2019088311A (ja) 2019-06-13
EP2970460B1 (en) 2020-04-29

Similar Documents

Publication Publication Date Title
IL261743B (en) and their uses 33–il antibodies against
IL261547B (en) Antibodies against pesidine and their uses
IL245040A0 (en) Antibodies against pdgfr-beta and their uses
IL243974B (en) Antibodies against –prlr and uses
ZA201508896B (en) Anti-c10orf54 antibodies and uses thereof
SG11201509618QA (en) Anti-b7-h5 antibodies and their uses
IL246287A0 (en) Fabs antibodies one by one and their uses
SG11201509116VA (en) Anti-tweakr antibodies and uses thereof
ZA201601294B (en) Anti-activin a antibodies and uses thereof
EP2953970A4 (en) TRANSTYRETIN ANTIBODIES AND USES THEREOF
ZA201601880B (en) Hetero-transglycosylase and uses thereof
GB201320992D0 (en) Complex and uses thereof
SG11201602760YA (en) Monoclonal olfml-3 antibodies and uses thereof
ZA201603596B (en) Fabs-in-tandem immunoglobulin and uses thereof
AU2013901830A0 (en) Antibodies and uses thereof